ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 612

Association of Platelet Endothelial Cell Adhesion Molecule-1 and beta1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis

Seong-Wook Kang1, Seung-Taek Song1, Su-Jin Yoo2, Mi-Kyoung Lim3, Dong-Hyuk Sheen4, In-Seol Yoo2, Jinhyun Kim1 and Seung-Cheol Shim1, 1Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 2Departmen of Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 3Rheumatology, Eulji University Hospital, Daejeon, South Korea, 4Department of Internal Medicine, Eulji University Hospital, Daejeon, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adhesion molecules, Ankylosing spondylitis (AS), integrins and uveitis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose

Genetic factors provide over 90% of the overall susceptibility to ankylosing spondylitis (AS) and recent studies have focused on non-major histocompatibility complex genes. The etiology of uveitis in AS has been suggested to involve two adhesion molecules including intercellular adhesion molecule (ICAM)-1 and leukocyte functional antigen (LFA)-1.

Platelet-endothelial cell adhesion molecule 1 (PECAM1) is a member of the immunoglobulin superfamily which is expressed on endothelial cells. There is emerging evidence to suggest that PECAM1 may be an important regulator of antigen induced cell activation of lymphocytes. The β1 integrin (ITGB1) can associate with different membrane proteins and cause signal transduction by interactions in the extracellular and trans-membrane domain. Therefore, we examined the association of PECAM1 and ITGB1 gene polymorphisms with development of uveitis in patients with AS.

Methods

We conducted a case–control study where 223 AS patients who met the Modified New York criteria and 239 ethnically matched controls were genotyped for 9 single nucleotide polymorphisms (SNPs) in the PECAM-1 promoter and gene. Genomic DNA was isolated from peripheral blood leukocytes by a standard phenol–chloroform method and a Golden Gate assay (Illumina, http://www.illumina.com) was used for genotyping.

Results

Conditional logistic regression was used to evaluate the association between the PECAM1 or ITGB1 SNPs with susceptibility to AS, and no significant association was found on both genes. However, in the subgroup analyses between AS patients with uveitis and those without, seven SNPs in PECAM1 gene were associated with the presence of uveitis, including rs1050382 (dominant model (DM), p=0.022), rs2812 (recessive model (RM), p=0.013), rs4968721 (DM, p=0.016), rs6808 (DM, p=0.011), rs6809 (DM, p=0.013), rs9899806 (DM, p=0.013) and rs9913080 (DM, p=0.019). In addition, seven polymorphisms in ITGB1 gene including rs11009147 (DM, p=0.012; co-dominant model (CDM), p=0.034), rs17468 (DM, p=0.012; CDM, p= 0.019), rs2153875 (CDM, p= 0.030), rs2230396 (DM, p=0.012; CDM, p=0.034), rs2488330 (DM, p=0.004; CDM, p=0.017), rs3780871 (DM, p=0.031) and rs7079624 (RM, p=0.004; CDM, p=0.017) were associated with uveitis development.

Conclusion

This is the first analysis of the PECAM1 and ITGB1 gene polymorphisms in AS, demonstrating a clear association with uveitis in AS. Given the functional role of PECAM-1 and ITGB1 variants in the immune system, larger studies are now warranted to elucidate the association of PECAM-1 and ITGB1 in the pathogenesis of uveitis in AS.

Table 1. Logistic analysis of PECAM1 polymorphisms and the risk of uveitis among AS patients                                                     

rs    No.   

Dominant    Model   

Recessive    Model   

Co-dominant    Model   

Odds   

(95%    CI)   

P.Value   

(adj.P.)   

Odds   

(95%    CI)   

P.Value   

(adj.P.)   

Odds   

(95%    CI)   

P.Value   

(adj.P.)   

rs1050382   

2.170   

(1.116-4.219)   

0.022   

(0.027)   

0.456   

(0.129-1.611)   

0.223   

(0.262)   

1.314   

(0.824-2.095)   

0.250   

(0.294)   

rs11079538   

1.623   

(0.745-3.537)   

0.222   

(0.261)   

1.289   

(0.568-2.924)   

0.543   

(0.571)   

1.345   

(0.821-2.202)   

0.238   

(0.297)   

rs2812   

2.190   

(0.620-7.736)   

0.223   

(0.247)   

0.424   

(0.215-0.837)   

0.013   

(0.024)   

0.732   

(0.457-1.173)   

0.195   

(0.300)   

rs4968721   

2.302   

(1.167-4.541)   

0.016   

(0.022)   

0.412   

(0.117-1.446)   

0.166   

(0.237)   

1.304   

(0.820-2.075)   

0.261   

(0.290)   

rs6808   

2.406   

(1.220-4.743)   

0.011   

(0.020)   

0.456   

(0.129-1.611)   

0.223   

(0.278)   

1.379   

(0.862-2.205)   

0.178   

(0.298)   

rs6809   

2.354   

(1.193-4.641)   

0.013   

(0.020)   

0.456   

(0.129-1.611)   

0.223   

(0.297)   

1.364   

(0.852-2.184)   

0.195   

(0.279)   

rs8065316   

1.124   

(0.490-2.578)   

0.781   

(0.822)   

1.774   

(0.908-3.468)   

0.093   

(0.155)   

1.360   

(0.848-2.180)   

0.201   

(0.268)   

rs9899806   

2.354   

(1.193-4.641)   

0.013   

(0.022)   

0.509   

(0.143-1.813)   

0.297   

(0.330)   

1.414   

(0.876-2.283)   

0.155   

(0.282)   

rs9913080   

2.252   

(1.141-4.443)   

0.019   

(0.025)   

0.392   

(0.112-1.373)   

0.143   

(0.220)   

1.270   

(0.800-2.016)   

0.310   

(0.326)   

 

Table 2. Logistic analysis of ITGB1 polymorphisms and the risk of uveitis among AS patients

rs number

Dominant Model

Recessive Model

Co-dominant Model

Odds

(95% CI)

P.Value

(adj.P.)

Odds

(95% CI)

P.Value

(adj.P.)

Odds

(95% CI)

P.Value

(adj.P.)

rs11009147

0.436

(0.226-0.839)

0.012

(0.021)

0.712

(0.273-1.858)

0.488

(0.596)

0.582

(0.353-0.960)

0.034

(0.046)

rs1187078

0.873

(0.261-2.921)

0.826

(0.865)

0.919

(0.486-1.737)

0.796

(0.834)

0.926

(0.560-1.532)

0.767

(0.804)

rs17468

0.436

(0.226-0.839)

0.012

(0.019)

0.563

(0.249-1.272)

0.167

(0.245)

0.589

(0.377-0.918)

0.019

(0.030)

rs2153875

0.527

(0.249-1.117)

0.094

(0.122)

0.465

(0.202-1.071)

0.072

(0.113)

0.582

(0.356-0.949)

0.030

(0.044)

rs2230396

0.436

(0.226-0.839)

0.012

(0.020)

0.712

(0.273-1.858)

0.488

(0.565)

0.582

(0.353-0.960)

0.034

(0.044)

rs2298141

1.340

(0.702-2.559)

0.374

(0.457)

3.718

(1.126-12.28)

0.031

(0.052)

1.508

(0.906-2.511)

0.113

(0.131)

rs2488330

0.390

(0.203-0.748)

0.004

(0.008)

0.712

(0.273-1.858)

0.488

(0.631)

0.546

(0.330-0.901)

0.017

(0.032)

rs2503997

1.278

(0.659-2.477)

0.466

(0.540)

1.308

(0.586-2.920)

0.511

(0.562)

1.205

(0.778-1.865)

0.401

(0.441)

rs3780871

0.268

(0.081-0.888)

0.031

(0.042)

0.745

(0.390-1.424)

0.374

(0.514)

0.662

(0.398-1.103)

0.113

(0.139)

rs7079624

1.403

(0.538-3.662)

0.488

(0.536)

2.560

(1.335-4.909)

0.004

(0.008)

1.830

(1.109-3.021)

0.017

(0.030)


Disclosure:

S. W. Kang,
None;

S. T. Song,
None;

S. J. Yoo,
None;

M. K. Lim,
None;

D. H. Sheen,
None;

I. S. Yoo,
None;

J. Kim,
None;

S. C. Shim,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-platelet-endothelial-cell-adhesion-molecule-1-and-beta1-integrin-gene-polymorphisms-with-uveitis-development-in-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology